Over 10 years, the hazard ratio—a comparison of disease rates over time—was 1.61 for participants with the condition versus those without it.Over 10 years, the hazard ratio—a comparison of disease rates over time—was 1.61 for participants with the condition versus those without it.
Participants with age-related expansion of mutated blood cells had an adjusted hazard ratio of 1.11 for progression to syndrome stage 4 compared with participants without…Participants with age-related expansion of mutated blood cells had an adjusted hazard ratio of 1.11 for progression to syndrome stage 4 compared with participants without the condition.
About 10% of preleukemic mutant clones actively suppressed or completely eliminated competing normal cells in a laboratory culture model.About 10% of preleukemic mutant clones actively suppressed or completely eliminated competing normal cells in a laboratory culture model.
Lab experiments showed that Olaparib treatment lengthened copied DNA tracts, increased DNA breaks and heightened drug sensitivity in cells lacking TET2, but not DNMT3A.Lab experiments showed that Olaparib treatment lengthened copied DNA tracts, increased DNA breaks and heightened drug sensitivity in cells lacking TET2, but not DNMT3A.
A yearly rise of at least 7.5% in mutated gene copies’ share best predicted cancer progression among patients with unexplained low counts of certain white blood cells.A yearly rise of at least 7.5% in mutated gene copies’ share best predicted cancer progression among patients with unexplained low counts of certain white blood cells.
In cohort data and cell models, ASXL1 mutations tracked with incident aortic stenosis and promoted valvular calcification that was reduced by IL-1 or IL-6 inhibition.In cohort data and cell models, ASXL1 mutations tracked with incident aortic stenosis and promoted valvular calcification that was reduced by IL-1 or IL-6 inhibition.